ADDRess - Translational Research for Persons with Abnormal DNA Damage Response
Disorders with Abnormal DNA Damage Response (DADDR) are rare genetic conditions with impaired DNA repair or maintenance. A shared feature among affected individuals is a strongly increased cancer risk. Treatment is commonly complicated due to the underlying genetic defect. Patients may suffer from excessive toxicity/secondary neoplasms, poor treatment response, and high mortality when treated with standard radiation/chemotherapy regimens. The development of treatment strategies is urgently needed. The proposed consortium is composed of patient representatives, physicians from the areas of psychosomatic medicine, gynecology, pediatric and adult hematology/oncology, radiology, pathology, and human genetics, and scientists specialized in cancer and DNA repair.
We aim at improving patient information/involvement as well as therapeutic guidance for health professionals; further elucidating disease-causing mechanisms; improving both psycho-social support and cancer surveillance employing innovative magnetic resonance imaging techniques in patients with Li-Fraumeni syndrome; advancing the use of brush biopsies employed as cancer surveillance tool for individuals with Fanconi anemia who exhibit an excessive oral cancer risk; identifying genetic markers of leukemia development; characterizing the genetic and epigenetic profiles of tumors to exploit these findings diagnostically and identify novel vulnerabilities for treatment and investigate new cancer therapies in pre-clinical disease models.Projects
- Coordination (Information, Communication, Data): Prof. Dr. Christian Peter Kratz, Prof. Dr. Lorenz Grigull, Dr. Beate Barbara Dörgeloh and Christina Maria Dutzmann, Hannover Medical School.
- Gene identification and functional analysis: Dr. Reinhard Kalb and Prof. Dr. Detlev Schindler, University of Würzburg (JMU).
- Optimization of the surveillance program for patients with DADDRs: Prof. Dr. Sarah Schott and Dr. Imad Maatouk, Heidelberg University and Heidelberg University Hospital.
- Early Cancer Diagnosis: Dr. Sebastian Bickelhaupt, Dr. Tristan Kuder, Dr. Katerina Deike-Hofmann, German Cancer Research Center (DKFZ) Heidelberg and Prof. Dr. Sarah Schott, Heidelberg University Hospital.
- Oral cancer surveillance for patients with Fanconi Anemia: Dr. Martin Schramm, Heinrich Heine University Düsseldorf and Düsseldorf University Hospital; Dr. Eunike Velleuer, Hospital Neuwerk Mönchengladbach and Ralf Dietrich, Deutsche Fanconi-Anämie-Hilfe e.V., Eschau.
- Marker in leukemia-development – 2 projects: Prof. Dr. Gudrun Goehring, Dr. Kathrin Thomay and Prof. Dr. Felicitas Thol, Hannover Medical School.
- Molecular tumour profiling: Prof. Dr. Stefan M. Pfister, Dr. Natalie Jäger and Dr. Martin Sill, German Cancer Research Center (DKFZ) Heidelberg.
- Pre-clinical models. Dr. Till Milde, German Cancer Research Center (DKFZ) Heidelberg.
Pediatric Hematology and Oncology
Hannover Medical School
Tel. +49 511 532-6711
Website: Website: www.krebs-praedisposition.de/register/address